开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

未开盘 02-03 16:08:18

2.700

+0.000

0.00%

最高2.770	最低2.650	成交量161.40万
今开2.700	昨收2.700	日振幅4.44%
总市值13.47亿	流通市值13.47亿	总股本4.99亿
成交额435.45万	换手率0.32%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":2.7,"timestamp":1770106098414,"preClose":2.7,"halted":0,"volume":1614000,"delay":0,"changeRate":0,"floatShares":499000000,"shares":499000000,"eps":-0.360537,"marketStatus":"未开盘","change":0,"latestTime":"02-03 16:08:18","open":2.7,"high":2.77,"low":2.65,"amount":4354485,"amplitude":0.044444,"askPrice":2.7,"askSize":5000,"bidPrice":2.67,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.367,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770168600000},"marketStatusCode":0,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":2.7,"openAndCloseTimeList":[[1770082200000,1770091200000],[1770094800000,1770105600000]],"volumeRatio":0.29856502323834017,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2608580600","title":"丹诺医药递表港交所；碧桂园称2025年完成房屋交付近17万套丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2608580600","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608580600?lang=zh_cn&edition=full","pubTime":"2026-02-04 01:12","pubTimestamp":1770138769,"startTime":"0","endTime":"0","summary":"｜2026年2月4日星期三｜NO.1东鹏饮料正式登陆港交所2月3日，东鹏饮料（HK09980，SH605499）正式登陆港交所主板。截至当日收盘，其港股报251.80港元/股，微涨1.53%，总市值1412亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602043640490921.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043640490921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1555","BK1515","BK1574","BK1507","BK1589","159938","BK1240","02007","BK1610","09939","BK1521","BK1161"],"gpt_icon":0},{"id":"2608808987","title":"【新股IPO】丹诺医药（苏州）股份有限公司 - B向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2608808987","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608808987?lang=zh_cn&edition=full","pubTime":"2026-02-03 23:24","pubTimestamp":1770132252,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所2月3日披露，丹诺医药 股份有限公司 - B向港交所主板提交上市申请，中信证券、农银国际为联席保荐人。公司核心产品利福特尼唑是自1982年发现幽门螺杆菌以来，全球首个且截至最后实际可行日期唯一治疗该细菌感染的新分子实体候选药物。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/ZWZlYzkyOGQ5ZGUzNDkxY2I2NjIxYmMxZDI0OGZjOTU0MjU2ODIxNjg3.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWZlYzkyOGQ5ZGUzNDkxY2I2NjIxYmMxZDI0OGZjOTU0MjU2ODIxNjg3.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974499","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","HEXmain","09939","BK1574","159938"],"gpt_icon":0},{"id":"2608874712","title":"丹诺医药冲刺港股：9个月亏损1.15亿 估值20亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608874712","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608874712?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:54","pubTimestamp":1770126850,"startTime":"0","endTime":"0","summary":"丹诺医药（苏州）股份有限公司（简称：“丹诺医药”）日前更新招股书，准备在港交所上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260203/6390575241379964971438826.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260203/6390575241379964971438826.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n32563/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4585","09939","BK1574","BK4588","VXUS","BK1515","159938","VT","BK1161"],"gpt_icon":0},{"id":"2608787830","title":"有产品已提前结幕！本周新发基金32只：广发易方达等27家公司竞技 电池、AI、医药、黄金赛道全览","url":"https://stock-news.laohu8.com/highlight/detail?id=2608787830","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608787830?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:29","pubTimestamp":1770118140,"startTime":"0","endTime":"0","summary":"　　2月3日，本周新发基金市场迎来一波发行小高峰，共有32只新产品启动认购，涉及广发、易方达、南方、景顺长城、招商基金、兴证全球、天弘、银华、永赢、西部利得等27家基金公司。　　从产品类型来看，本周新发股票型基金14只、混合型基金7只、债券型基金6只、FOF基金6只，涵盖不同风险收益特征，为投资者提供了多层次配置选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-02-03/doc-inhkpvfi7283506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","SGUmain","09939","MGCmain","BK4504","BK1161","BK4535","BK4585","159934","1OZmain","BK1574","159796","SGCmain","BK1515","BK4588","QOmain","159831","GCmain","518880","DUST"],"gpt_icon":1},{"id":"2608875572","title":"283只医药股披露2025年业绩预告：药明康德最能赚、创新药企业走向盈利分界线，疫苗企业业绩承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2608875572","media":"每经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608875572?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:52","pubTimestamp":1770115974,"startTime":"0","endTime":"0","summary":"Wind数据显示，截至1月31日，共有283只医药股披露了2025年业绩预告。赛诺医疗预计，公司2025年归母净利润为4300万元至5000万元，同比增长2767%至3233%。此外，披露2025年度业绩预告的医药股中，药明康德预计净利润为191.51亿元，创公司上市以来的归母净利润新高。多家创新药企业预计扭亏、减亏披露业绩预告的创新药企中，不少企业出现净利扭亏、减亏的情形。此外，盟科药业、君实生物等创新药企虽未实现盈利，但已大幅减亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203185354a6ce4350&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203185354a6ce4350&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","LU2242644610.SGD","LU0708995583.HKD","BK1574","LU2125910500.SGD","06978","BK1515","01877","BK1576","LU0320764599.SGD","02359","LU1046422090.SGD","09939","LU0052750758.USD","LU2045819591.USD","BK1141","BK1583"],"gpt_icon":0},{"id":"2608182681","title":"晨光生物：主要产品广泛应用于食品饮料、调味品、营养保健、医药、香精香料、动保及饲料蛋白等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2608182681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608182681?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:42","pubTimestamp":1770108129,"startTime":"0","endTime":"0","summary":"证券之星消息，晨光生物(300138)02月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的下游主要涉及哪些行业，包括哪些知名公司？晨光生物回复：您好，公司主要产品广泛应用于食品饮料、调味品、营养保健、医药、香精香料、动保及饲料蛋白等领域。关于客户信息，因涉及商业机密，不便具体透露。谢谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300028118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000807.SH","159843","BK1515","BK1574","BK0238","300138","159938","09939","BK1161"],"gpt_icon":0},{"id":"2608786488","title":"【国海医药 | 英硅智能】与齐鲁制药达成合作，持续验证AI制药能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2608786488","media":"国海Healthcare","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608786488?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:16","pubTimestamp":1770106566,"startTime":"0","endTime":"0","summary":"事件：2026年1月27日，英硅智能发布公告：公司与齐鲁制药签署战略合作协议，双方将围绕心血管与代谢类疾病领域，利用英硅智能的Pharma.AI平台进行小分子抑制剂的研发。持续达成研发合作，AI制药能力不断被认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020317010697a4a3c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020317010697a4a3c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","01477","BK1141","BK1191","BK1574","03696","09939"],"gpt_icon":0},{"id":"2608823123","title":"吉林敖东：聚焦医药主业，持续推进产品创新研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2608823123","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608823123?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:12","pubTimestamp":1770106338,"startTime":"0","endTime":"0","summary":"证券之星消息，吉林敖东02月03日在投资者关系平台上答复投资者关心的问题。希望公司领导层好好考虑转型创新药相关事宜。公司高度关注医药行业集采常态化及创新药发展趋势，聚焦医药主业，持续推进产品创新研发，并通过产业基金布局生物制药等创新领域。公司将结合医药全产业链优势，科学统筹研发投入，审慎评估创新药研发方向与布局节奏，稳步推进研发工作，持续提升公司核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300025618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK0086","BK1515","BK1574","159938","BK0028","000623","BK0239","BK0012","BK0201","BK0188","BK0074","BK1161"],"gpt_icon":0},{"id":"2608877183","title":"华昊中天医药-B盘中异动 股价大涨6.94%报3.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608877183","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608877183?lang=zh_cn&edition=full","pubTime":"2026-02-03 14:59","pubTimestamp":1770101976,"startTime":"0","endTime":"0","summary":"2026年02月03日下午盘14时59分，华昊中天医药-B股票出现异动，股价急速拉升6.94%。截至发稿，该股报3.700港元/股，成交量1.68万股，换手率0.01%，振幅6.94%。资金方面，该股资金流入2.4268万港元，流出3.3908万港元。华昊中天医药-B股票所在的生物技术行业中，整体涨幅为1.76%。华昊中天医药-B公司简介：公司是一家专注于肿瘤治疗领域的创新药企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203145936a4765ca7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203145936a4765ca7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09939","02563","BK1515","BK1161"],"gpt_icon":0},{"id":"2608823180","title":"自有销售团队尚未建立、偿债能力堪忧，征祥医药IPO“闯关”挑战重重","url":"https://stock-news.laohu8.com/highlight/detail?id=2608823180","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608823180?lang=zh_cn&edition=full","pubTime":"2026-02-03 14:18","pubTimestamp":1770099530,"startTime":"0","endTime":"0","summary":"招股书显示，截至 2024 年 12 月 31 日止年度以及截至 2024 年、2025 年 9 月 30 日止九个月，征祥医药分别亏损1.45亿元、1.27亿元及 1.45亿元，不到三年累计亏损超4亿元。持续亏损背后，是征祥医药居高不下的研发投入与微薄的收入形成的强烈反差。更值得警惕的是，征祥医药存在大额 “赎回负债重新计量”损失，同期分别为5090万元、3810万元及 4810万元。更值得注意的是，征祥医药尚未建立自有销售团队，商业化能力完全依赖外部合作方。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8qRVyR4TynU","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","159938","BK1515","BK1574","09939"],"gpt_icon":0},{"id":"2608635817","title":"【国联民生医药】艾力斯2025年业绩预告点评：肺癌领域深度布局，自主商业化能力持续增强","url":"https://stock-news.laohu8.com/highlight/detail?id=2608635817","media":"医耀科技创新骑手","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608635817?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:48","pubTimestamp":1770040110,"startTime":"0","endTime":"0","summary":"公司肺癌领域深度布局，引进戈来雷塞和普拉替尼。2025 年 6月，戈来雷塞正式开启商业化，艾力斯建立了罕见靶点专业团队负责产品核心市场的销售。自主商业化能力持续强化，医保谈判顺利。新版目录将于2026年1月1日起正式执行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202220102a473a639&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202220102a473a639&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1564","BK1574","09939","BK1515","BK1147","01456"],"gpt_icon":0},{"id":"2608676850","title":"济川药业(600566.SZ)子公司与普祺医药签署独家商业化合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2608676850","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608676850?lang=zh_cn&edition=full","pubTime":"2026-02-02 18:17","pubTimestamp":1770027475,"startTime":"0","endTime":"0","summary":"智通财经APP讯，济川药业(600566.SZ)公告，公司全资子公司济川药业集团有限公司(“济川有限”)与北京普祺医药科技股份有限公司(“普祺医药”)签署独家商业化合作协议，约定授权济川有限在合作期限内独家负责普祺医药拥有的普美昔替尼(PG-011)鼻喷雾剂在中国的商业化。济川有限向普祺医药支付最高不超过1亿元(含税)的独家商业化权益的对价。公告显示，普美昔替尼(PG-011)是一款自主研发、具有完全知识产权的JAK1/2抑制剂，用于治疗过敏性鼻炎。交易完成后，公司将进一步加强产品线的丰富程度，有利于公司业务的可持续发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0012","159938","BK0187","BK0201","BK0077","BK1515","BK0028","BK0188","BK1161","600566","09939","BK1574"],"gpt_icon":0},{"id":"1190948153","title":"开拓药业（9939）更新1月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1190948153","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190948153?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:13","pubTimestamp":1770023581,"startTime":"0","endTime":"0","summary":"开拓药业有限公司（09939）于2026年2月2日公布2026年1月股份变动月报表。截至1月31日，公司法定注册股本维持在700,000,000股，每股面值0.0001美元，注册股本总额为70,000美元。相比上个月无任何增减变动。\n公司已发行股份总数同样保持在498,660,100股，未发生新的股份发行、购回或注销活动。公司合乎香港联交所的最低公众持股量要求，确认遵守香港联交所《上市规则》及相关法律规范。\n公告由公司主席、执行董事及行政总裁童友之签署。整体而言，截至1月底，公司股本仍保持稳定，无任何实质性变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939"],"gpt_icon":0},{"id":"2608518028","title":"2月2日热景生物跌5.36%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608518028","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608518028?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:40","pubTimestamp":1770021655,"startTime":"0","endTime":"0","summary":"证券之星消息，2月2日热景生物跌5.36%，收盘报137.64元，换手率1.62%，成交量1.5万手，成交额2.11亿元。重仓热景生物的前十大公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共53家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为72.69亿元，最新净值1.7308，较上一交易日下跌1.8%，近一年上涨39.13%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","09939","BK1574","BK0239","688068","159938"],"gpt_icon":0},{"id":"2608850786","title":"每日卖空追踪 | 同源康医药-B 02月02日卖空量成交9000股，卖空比例为0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608850786","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608850786?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:30","pubTimestamp":1770021030,"startTime":"0","endTime":"0","summary":"同源康医药-B北京时间02月02日，跌3%，卖空量成交9000股，较上一交易日减少50%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163651a6c985c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163651a6c985c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","BK1161","09939","BK1574","BK1515"],"gpt_icon":0},{"id":"2608713850","title":"同源康医药-B02月02日遭主力抛售50.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608713850","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608713850?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:15","pubTimestamp":1770020129,"startTime":"0","endTime":"0","summary":"02月02日, 同源康医药-B股价跌3.00%，报收12.27元，成交金额3124.7万元，换手率0.67%，振幅6.09%，量比0.58。同源康医药-B今日主力资金净流出50.3万元，连续5日净流出，上一交易日主力净流出65.1万元。该股近5个交易日下跌3.39%，主力资金累计净流出742.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入427.8万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202161753a6c97173&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202161753a6c97173&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","BK1161","BK1574","BK1515","09939"],"gpt_icon":0},{"id":"2608891072","title":"泛微网络：中标广州白云山医药集团股份有限公司采购项目，中标金额为358.00万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608891072","media":"同壁财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608891072?lang=zh_cn&edition=full","pubTime":"2026-02-02 12:32","pubTimestamp":1770006746,"startTime":"0","endTime":"0","summary":"同壁财经讯，企查查数据显示，根据《广州白云山医药集团股份有限公司一体化协同办公平台采购项目-中标公告》，泛微网络科技股份有限公司于2026年2月2日公告中标广州白云山医药集团股份有限公司采购项目，中标金额为358.00万元。2025年上半年公司营业收入为8.08亿元，营业收入增长率为-8.79%，归属母公司净利润为0.66亿元，归属母公司净利润增长率为38.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202124830a6c8b759&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202124830a6c8b759&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1606","BK1515","BK1161","BK1191","00874","BK1197","BK1521","BK1574"],"gpt_icon":0},{"id":"2608358855","title":"开拓药业-B盘中异动 早盘股价大跌5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608358855","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608358855?lang=zh_cn&edition=full","pubTime":"2026-02-02 10:06","pubTimestamp":1769998018,"startTime":"0","endTime":"0","summary":"2026年02月02日早盘10时06分，开拓药业-B股票出现波动，股价急速下挫5.32%。截至发稿，该股报2.670港元/股，成交量63.45万股，换手率0.13%，振幅5.32%。开拓药业-B股票所在的药品行业中，整体跌幅为0.52%。其相关个股中，康哲药业、励晶太平洋、海王英特龙涨幅较大，振幅较大的相关个股有康哲药业、宝济药业-B、英硅智能，振幅分别为6.34%、5.77%、5.72%。该公司在皮科领域有两款核心药物KX-826及GT20029。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202100658a6c829e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202100658a6c829e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2608884860","title":"股市必读：欧康医药（920230）预计2025年全年归属净利润盈利1000万元至1300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608884860","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608884860?lang=zh_cn&edition=full","pubTime":"2026-02-02 05:12","pubTimestamp":1769980336,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，欧康医药报收于12.87元，下跌0.62%，换手率2.3%，成交量1.09万手，成交额1422.89万元。业绩披露要点业绩预告欧康医药发布业绩预告，预计2025年全年归属净利润盈利1000万元至1300万元。公司公告汇总2025年年度业绩预告公告成都欧康医药股份有限公司预计2025年度归属于上市公司股东的净利润为1,000万元至1,300万元，较上年同期2,244.23万元下降55.44%至42.07%。上述财务数据为初步核算结果，未经审计，最终数据以公司2025年年度报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938"],"gpt_icon":0},{"id":"2608806882","title":"最高预增超32倍 283只医药股“剧透”业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2608806882","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608806882?lang=zh_cn&edition=full","pubTime":"2026-02-01 23:55","pubTimestamp":1769961300,"startTime":"0","endTime":"0","summary":"　　2025年，A股医药股的业绩“冷暖交织”。Wind数据显示，截至2月1日，共有283只医药股“剧透”2025年的业绩情况。按预告净利润上限看，共有160股的归属净利润同比增长，其中赛诺医疗成为A股药企的净利“预增王”，最高预增超32倍。在过半数企业业绩预增的同时，也有超120家企业的业绩预减，其中更有39股面临上市后的首次亏损，不乏智飞生物、珍宝岛、新诺威等知名企业。君实生物、盟科药业等创新药企虽未盈利，但减亏趋势明显。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2026-02-01/doc-inhkitqv4729858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1574","159938","BK1161","BK1515"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.1234},{"period":"1month","weight":0.3235},{"period":"3month","weight":0.5517},{"period":"6month","weight":0.2919},{"period":"1year","weight":2},{"period":"ytd","weight":0.3776}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":0.0188},{"period":"3month","weight":0.0347},{"period":"6month","weight":0.0699},{"period":"1year","weight":0.3273},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.176165},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}